BR112015022385A2 - droga para uma doença respiratória - Google Patents
droga para uma doença respiratóriaInfo
- Publication number
- BR112015022385A2 BR112015022385A2 BR112015022385A BR112015022385A BR112015022385A2 BR 112015022385 A2 BR112015022385 A2 BR 112015022385A2 BR 112015022385 A BR112015022385 A BR 112015022385A BR 112015022385 A BR112015022385 A BR 112015022385A BR 112015022385 A2 BR112015022385 A2 BR 112015022385A2
- Authority
- BR
- Brazil
- Prior art keywords
- group
- alkyl
- halogenated
- alkoxy
- groups
- Prior art date
Links
- 208000023504 respiratory system disease Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000005189 alkyl hydroxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 230000000069 prophylactic effect Effects 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1 / 1 resumo “droga para uma doenã‡a respiratã“riaâ€� ㉠fornecido um agente terapãªutico e/ou profilã¡tico para doenã§as respiratã³rias, ou um agente terapãªutico e/ou profilã¡tico para doenã§as mediadas por canal de sã³dio. um agente farmacãªutico que contã©m, como um ingrediente ativo, um composto representado pela fã³rmula (i) ou um sal 1 farmacologicamente aceitã¡vel do mesmo. na fã³rmula (i), cada um de ar e 2 1 2 ar representa um grupo heteroarila ou um grupo arila; cada um de r , r e 3 r representa um ã¡tomo de hidrogãªnio, um ã¡tomo de halogãªnio, um grupo alquila c -c , um grupo alquila c -c halogenado, um grupo hidrã³xi alquila 1 6 1 6 c -c , um grupo alcã³xi c -c alquila c -c , um grupo cicloalquila c -c ou 1 6 1 6 1 6 3 7 4 5 um grupo ciano; cada r e r representa um ã¡tomo de hidrogãªnio, um ã¡tomo de halogãªnio, um grupo alquila c -c , um grupo alquila c -c halogenado, 1 6 1 6 um grupo hidroxila, um grupo hidrã³xi alquila c -c , um grupo alcã³xi c -c 1 6 1 6 alquila c -c , um grupo cicloaquila c -c ou um grupo alcã³xi c -c ; e n 1 6 3 7 1 6 representa um nãºmero inteiro de 1-3. neste contexto, o grupo heteroarila e o grupo arila podem apresentar um ou dois grupos que sã£o independentemente selecionados entre um ã¡tomo de halogãªnio, um grupo alquila c -c , um grupo 1 6 alquila c -c halogenado, um grupo hidroxila, um grupo hidrã³xi alquila c - 1 6 1 c , um grupo alcã³xi c -c alquila c -c , um grupo cicloalquila c -c , um 6 1 6 1 6 3 7 grupo carboxila, um grupo ciano, um grupo amino, um grupo alquilamino c - 1 c e um grupo dialquilamino c -c , e em casos onde dois grupos estã£o 3 1 3 contidos, os grupos podem ser os mesmos ou diferentes um do outro. ( ) n (i)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013052278 | 2013-03-14 | ||
| PCT/JP2014/056606 WO2014142221A1 (ja) | 2013-03-14 | 2014-03-13 | 呼吸器疾患用薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015022385A2 true BR112015022385A2 (pt) | 2017-07-18 |
Family
ID=51536872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015022385A BR112015022385A2 (pt) | 2013-03-14 | 2014-03-13 | droga para uma doença respiratória |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9597330B2 (pt) |
| EP (1) | EP2974730B1 (pt) |
| JP (1) | JP6208212B2 (pt) |
| KR (1) | KR20150126620A (pt) |
| CN (1) | CN105073114B (pt) |
| BR (1) | BR112015022385A2 (pt) |
| CA (1) | CA2905613C (pt) |
| ES (1) | ES2663798T3 (pt) |
| TW (1) | TWI630204B (pt) |
| WO (1) | WO2014142221A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2617512C1 (ru) * | 2015-10-23 | 2017-04-25 | Общество с ограниченной ответственностью "Нормофарм" | Средство с антистрессовой, анксиолитической и антидепрессивной активностью и композиция на его основе |
| EP3372583A4 (en) * | 2015-11-06 | 2019-06-05 | Daiichi Sankyo Company, Limited | PROCESS FOR REMOVING A DIMETHOXYBENZYL GROUP |
| JP2019532077A (ja) * | 2016-10-17 | 2019-11-07 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| CN110546148A (zh) | 2017-03-24 | 2019-12-06 | 基因泰克公司 | 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物 |
| TW202000651A (zh) | 2018-02-26 | 2020-01-01 | 美商建南德克公司 | 治療性組成物及其使用方法 |
| US10947251B2 (en) | 2018-03-30 | 2021-03-16 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| CN112979719B (zh) * | 2021-02-24 | 2022-11-01 | 厦门稀土材料研究所 | 二茂铁甲酸肟酯类衍生物、制备方法及其用途 |
| CN114805019B (zh) * | 2022-04-25 | 2024-03-12 | 华东师范大学 | 一种基于连续流反应技术合成2-芳基-1-环己醇的方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6222048B1 (en) | 1995-12-18 | 2001-04-24 | Merck Frosst Canada & Co. | Diaryl-2-(5H)-furanones as Cox-2 inhibitors |
| WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| WO2009012242A2 (en) | 2007-07-13 | 2009-01-22 | Icagen, Inc. | Sodium channel inhibitors |
| JP5053459B2 (ja) | 2009-01-12 | 2012-10-17 | アイカジェン， インコーポレイテッド | スルホンアミド誘導体 |
| TW201139406A (en) | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
| US9096558B2 (en) * | 2010-07-09 | 2015-08-04 | Pfizer Limited | N-sulfonylbenzamide compounds |
| JP2014518281A (ja) * | 2011-07-06 | 2014-07-28 | グラクソ グループ リミテッド | 電位依存性ナトリウムチャネル遮断薬 |
| WO2013064983A1 (en) * | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| US8889741B2 (en) * | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
-
2014
- 2014-03-13 US US14/776,315 patent/US9597330B2/en not_active Expired - Fee Related
- 2014-03-13 ES ES14763747.4T patent/ES2663798T3/es active Active
- 2014-03-13 EP EP14763747.4A patent/EP2974730B1/en not_active Not-in-force
- 2014-03-13 TW TW103108895A patent/TWI630204B/zh not_active IP Right Cessation
- 2014-03-13 BR BR112015022385A patent/BR112015022385A2/pt not_active Application Discontinuation
- 2014-03-13 JP JP2015505543A patent/JP6208212B2/ja not_active Expired - Fee Related
- 2014-03-13 CA CA2905613A patent/CA2905613C/en not_active Expired - Fee Related
- 2014-03-13 WO PCT/JP2014/056606 patent/WO2014142221A1/ja active Application Filing
- 2014-03-13 CN CN201480015443.6A patent/CN105073114B/zh not_active Expired - Fee Related
- 2014-03-13 KR KR1020157025025A patent/KR20150126620A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US9597330B2 (en) | 2017-03-21 |
| CN105073114A (zh) | 2015-11-18 |
| EP2974730A1 (en) | 2016-01-20 |
| CN105073114B (zh) | 2017-07-28 |
| CA2905613A1 (en) | 2014-09-18 |
| TW201514168A (zh) | 2015-04-16 |
| JP6208212B2 (ja) | 2017-10-04 |
| ES2663798T3 (es) | 2018-04-17 |
| EP2974730B1 (en) | 2018-01-31 |
| CA2905613C (en) | 2017-11-28 |
| KR20150126620A (ko) | 2015-11-12 |
| JPWO2014142221A1 (ja) | 2017-02-16 |
| WO2014142221A1 (ja) | 2014-09-18 |
| US20160038486A1 (en) | 2016-02-11 |
| TWI630204B (zh) | 2018-07-21 |
| EP2974730A4 (en) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015022385A2 (pt) | droga para uma doença respiratória | |
| EA201892395A1 (ru) | Лекарственные составы ингибитора lsd1 | |
| BR112015014585A2 (pt) | composto, composição farmacêutica, e, método de tratamento de um ser humano | |
| CY1118379T1 (el) | Αναστολεις ιου ηπατιτιδας c | |
| BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
| BR112015013611A2 (pt) | composto, e, composição farmacêutica | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| BR112015022643A2 (pt) | inibidores diidro-pirrolpiridinona | |
| EA201892219A1 (ru) | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге | |
| EA201892216A1 (ru) | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге | |
| BR112016015818A2 (pt) | Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1 | |
| EA201491548A1 (ru) | 2'-замещенные карбануклеозидные аналоги для противовирусного лечения | |
| BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| BR112014019478A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença. | |
| EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
| BR112015015477A2 (pt) | derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| NZ711424A (en) | Pyridine derivatives as soft rock inhibitors | |
| BR112014000792A2 (pt) | compostos de piperidinila para uso como inibidores da tanquirase | |
| DOP2014000059A (es) | Derivados de estra1,3,5(10),16tetraen3carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
| BR112015027440A2 (pt) | DERIVADO DE [1,2,4]TRIAZOL[4,3-a]PIRIDINA, MÉTODO DE PREPA-RAÇÃO OU APLICAÇÃO MÉDICA DO DERIVADO | |
| BR112015022758A2 (pt) | derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia | |
| BR112015022092A2 (pt) | derivado de di-hidropiridazina-3,5-diona | |
| BR112013017302A2 (pt) | formulações de imunossupressor | |
| BR112016026552A8 (pt) | derivados de carboxamida, seus usos, composição farmacêutica, e combinação |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
| B07E | Notice of approval relating to section 229 industrial property law | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure | ||
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |